Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: A population-based study

Amy J. Hobbs, Nigel T. Brockton, T. Wayne Matthews, Shamir P. Chandarana, Pinaki Bose, Kelly Guggisberg, Gordon H. Fick, Joseph C. Dort

Research output: Contribution to journalArticle

Abstract

Background: The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (SCC) is increasing and has better survival than non-HPV related oropharyngeal SCC. This study compared surgical to nonsurgical treatments and demographic, clinical, and survival differences in patients with oropharyngeal SCC, stratified by p16 status. Methods: We assembled a cohort of adult patients with oropharyngeal SCC diagnosed between 2000 and 2008 in Alberta. The tumor p16 biomarker was measured using fluorescent immunohistochemistry. Results: In this cohort, p16 data were available for 115 of 357 patients; and 66% (n = 76) were p16-positive. Patients with p16 data had comparable outcomes to those without. Surgically treated p16-negative patients had improved 5-year disease-specific survival (DSS) and overall survival (OS) compared with nonsurgical patients. There were no differences in survival outcomes between surgical and nonsurgical treatment for patients with p16-positive disease. Conclusion: Patients with p16-positive oropharyngeal SCC had similar outcomes regardless of treatment. Patients with p16-negative tumors may benefit from primary surgery with postoperative adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)2187-2199
Number of pages13
JournalHead and Neck
Volume39
Issue number11
DOIs
StatePublished - Nov 1 2017
Externally publishedYes

Fingerprint

Alberta
Canada
Squamous Cell Carcinoma
Population
Survival
Therapeutics
Tumor Biomarkers
Immunohistochemistry
Demography

Keywords

  • chemoradiation
  • human papillomavirus
  • oropharyngeal squamous cell carcinoma
  • p16
  • surgery

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Hobbs, A. J., Brockton, N. T., Matthews, T. W., Chandarana, S. P., Bose, P., Guggisberg, K., ... Dort, J. C. (2017). Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: A population-based study. Head and Neck, 39(11), 2187-2199. https://doi.org/10.1002/hed.24889

Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada : A population-based study. / Hobbs, Amy J.; Brockton, Nigel T.; Matthews, T. Wayne; Chandarana, Shamir P.; Bose, Pinaki; Guggisberg, Kelly; Fick, Gordon H.; Dort, Joseph C.

In: Head and Neck, Vol. 39, No. 11, 01.11.2017, p. 2187-2199.

Research output: Contribution to journalArticle

Hobbs, AJ, Brockton, NT, Matthews, TW, Chandarana, SP, Bose, P, Guggisberg, K, Fick, GH & Dort, JC 2017, 'Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: A population-based study', Head and Neck, vol. 39, no. 11, pp. 2187-2199. https://doi.org/10.1002/hed.24889
Hobbs AJ, Brockton NT, Matthews TW, Chandarana SP, Bose P, Guggisberg K et al. Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: A population-based study. Head and Neck. 2017 Nov 1;39(11):2187-2199. https://doi.org/10.1002/hed.24889
Hobbs, Amy J. ; Brockton, Nigel T. ; Matthews, T. Wayne ; Chandarana, Shamir P. ; Bose, Pinaki ; Guggisberg, Kelly ; Fick, Gordon H. ; Dort, Joseph C. / Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada : A population-based study. In: Head and Neck. 2017 ; Vol. 39, No. 11. pp. 2187-2199.
@article{30d725bf3db84b9c936caf959836426c,
title = "Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: A population-based study",
abstract = "Background: The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (SCC) is increasing and has better survival than non-HPV related oropharyngeal SCC. This study compared surgical to nonsurgical treatments and demographic, clinical, and survival differences in patients with oropharyngeal SCC, stratified by p16 status. Methods: We assembled a cohort of adult patients with oropharyngeal SCC diagnosed between 2000 and 2008 in Alberta. The tumor p16 biomarker was measured using fluorescent immunohistochemistry. Results: In this cohort, p16 data were available for 115 of 357 patients; and 66{\%} (n = 76) were p16-positive. Patients with p16 data had comparable outcomes to those without. Surgically treated p16-negative patients had improved 5-year disease-specific survival (DSS) and overall survival (OS) compared with nonsurgical patients. There were no differences in survival outcomes between surgical and nonsurgical treatment for patients with p16-positive disease. Conclusion: Patients with p16-positive oropharyngeal SCC had similar outcomes regardless of treatment. Patients with p16-negative tumors may benefit from primary surgery with postoperative adjuvant therapy.",
keywords = "chemoradiation, human papillomavirus, oropharyngeal squamous cell carcinoma, p16, surgery",
author = "Hobbs, {Amy J.} and Brockton, {Nigel T.} and Matthews, {T. Wayne} and Chandarana, {Shamir P.} and Pinaki Bose and Kelly Guggisberg and Fick, {Gordon H.} and Dort, {Joseph C.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1002/hed.24889",
language = "English (US)",
volume = "39",
pages = "2187--2199",
journal = "Head and Neck Surgery",
issn = "0148-6403",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada

T2 - A population-based study

AU - Hobbs, Amy J.

AU - Brockton, Nigel T.

AU - Matthews, T. Wayne

AU - Chandarana, Shamir P.

AU - Bose, Pinaki

AU - Guggisberg, Kelly

AU - Fick, Gordon H.

AU - Dort, Joseph C.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Background: The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (SCC) is increasing and has better survival than non-HPV related oropharyngeal SCC. This study compared surgical to nonsurgical treatments and demographic, clinical, and survival differences in patients with oropharyngeal SCC, stratified by p16 status. Methods: We assembled a cohort of adult patients with oropharyngeal SCC diagnosed between 2000 and 2008 in Alberta. The tumor p16 biomarker was measured using fluorescent immunohistochemistry. Results: In this cohort, p16 data were available for 115 of 357 patients; and 66% (n = 76) were p16-positive. Patients with p16 data had comparable outcomes to those without. Surgically treated p16-negative patients had improved 5-year disease-specific survival (DSS) and overall survival (OS) compared with nonsurgical patients. There were no differences in survival outcomes between surgical and nonsurgical treatment for patients with p16-positive disease. Conclusion: Patients with p16-positive oropharyngeal SCC had similar outcomes regardless of treatment. Patients with p16-negative tumors may benefit from primary surgery with postoperative adjuvant therapy.

AB - Background: The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (SCC) is increasing and has better survival than non-HPV related oropharyngeal SCC. This study compared surgical to nonsurgical treatments and demographic, clinical, and survival differences in patients with oropharyngeal SCC, stratified by p16 status. Methods: We assembled a cohort of adult patients with oropharyngeal SCC diagnosed between 2000 and 2008 in Alberta. The tumor p16 biomarker was measured using fluorescent immunohistochemistry. Results: In this cohort, p16 data were available for 115 of 357 patients; and 66% (n = 76) were p16-positive. Patients with p16 data had comparable outcomes to those without. Surgically treated p16-negative patients had improved 5-year disease-specific survival (DSS) and overall survival (OS) compared with nonsurgical patients. There were no differences in survival outcomes between surgical and nonsurgical treatment for patients with p16-positive disease. Conclusion: Patients with p16-positive oropharyngeal SCC had similar outcomes regardless of treatment. Patients with p16-negative tumors may benefit from primary surgery with postoperative adjuvant therapy.

KW - chemoradiation

KW - human papillomavirus

KW - oropharyngeal squamous cell carcinoma

KW - p16

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=85031676243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031676243&partnerID=8YFLogxK

U2 - 10.1002/hed.24889

DO - 10.1002/hed.24889

M3 - Article

C2 - 28782304

AN - SCOPUS:85031676243

VL - 39

SP - 2187

EP - 2199

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 0148-6403

IS - 11

ER -